MedTrace Logo

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1360

Last updated 2021-10-12

Study results available
· View outcomes & findings →

Summary

This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.

Conditions

Interventions

DRUG

Hydroxychloroquine

oral self administered tablet

DRUG

Placebo oral tablet

oral self administered tablet

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Adrian Hernandez

    lead OTHER

Principal Investigators

  • Adrian Hernandez, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-22
Primary Completion
2020-12-10
Completion
2021-01-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04334148 on ClinicalTrials.gov